Eosinophil Subpopulations in Eosinophilic-associated Diseases (IREOS)

March 27, 2025 updated by: Alessandra Vultaggio, University of Florence

Exploring Inflammatory and Regulatory Eosinophil Subpopulations: the Path to Precision Medicine for the Treatment of Eosinophilic-associated Diseases

This single-center, non-commercial study will involve 160 participants (80 with eosinophilic asthma (EA), 30 with eosinophilic granulomatosis with polyangiitis (EGPA), 25 with hypereosinophilic syndrome (HES), and 25 healthy donors) to investigate eosinophil subpopulations in these diseases. The study will run from Q4 2024 to Q4 2026.

Objectives:

Primary: To verify two eosinophil subpopulations (iEos and rEos) in EGPA and HES and analyze the role of type 2 cytokines on their plasticity.

Secondary: Compare iEos proportion between different eosinophilic diseases and correlate with disease severity.

Exploratory: Assess the effect of mepolizumab on eosinophil subpopulations in vitro.

Population: Adults aged 18-75 with EA, EGPA, or HES, and healthy controls. EA patients must have >300 eosinophils/mcL, EGPA requires asthma + eosinophilia + other specific features, and HES requires high eosinophil counts (>1500 cells/mL).

Methods: Data will be analyzed using Mann-Whitney U, ANOVA, and Spearman correlation tests, with results presented as mean ± SEM.

This study will help explore eosinophil behavior in eosinophilic diseases and evaluate mepolizumab's effects on these cells.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Introduction Eosinophils (Eos) play a crucial role in both normal physiological functions and various pathological conditions. They are primarily recognized for their involvement in immune defense against infections, including parasitic, bacterial, and viral infections, as well as in cancer surveillance. However, they are also key contributors to eosinophil-associated diseases (EADs) such as bronchial asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES).

Recent research has revealed that eosinophils exist in distinct subpopulations with unique phenotypic characteristics and functions. These subpopulations, referred to as resident eosinophils (rEos) and inflammatory eosinophils (iEos), have been primarily studied in healthy tissues and in conditions like severe eosinophilic asthma (SEA) and CRSwNP. While rEos are believed to contribute to tissue homeostasis and immune regulation, iEos are associated with inflammatory responses. Studies in mouse models have demonstrated the presence of these subpopulations in lung tissue, but their role in human disease remains less understood.

Although there is emerging evidence suggesting the presence of these eosinophil subsets in human peripheral blood and nasal polyp tissue, they have not been fully characterized in other EADs such as EGPA and HES. Understanding whether these subpopulations exist in these diseases and how they are influenced by type 2 cytokines could provide valuable insights into disease mechanisms. Furthermore, as eosinophil-targeted therapies such as Mepolizumab (an anti-IL-5 monoclonal antibody) are already in clinical use, clarifying their specific effects on these eosinophil subsets could help optimize treatment strategies.

Study Rationale and Objectives This study aims to expand on previous findings by investigating whether distinct eosinophil subpopulations exist in EGPA and HES patients. Additionally, the study seeks to analyze how type 2 cytokines influence the differentiation and function of these eosinophil subsets. A key aspect of this research is assessing the effect of Mepolizumab on rEos and iEos, particularly whether it selectively targets inflammatory eosinophils without affecting homeostatic eosinophils.

The primary objectives of this study include:

Confirming the presence of two distinct eosinophil subpopulations in EGPA and HES.

Investigating the impact of type 2 cytokines on eosinophil plasticity and function.

Secondary objectives involve comparing iEos proportions across different eosinophilic diseases and analyzing their correlation with disease severity. Additionally, the study will explore how in vitro exposure to Mepolizumab affects the balance between rEos and iEos in EGPA and HES patients.

Study Design The study will involve patients diagnosed with severe eosinophilic asthma (SEA), EGPA, and HES, along with a control group of healthy donors. Blood samples will be collected and analyzed using flow cytometry to characterize eosinophil subpopulations. In vitro experiments will assess the effects of type 2 cytokines (such as IL-5, IL-3, GM-CSF, IL-4, and IL-13) on these eosinophil subsets, as well as the impact of Mepolizumab.

Subject Selection and Eligibility Criteria Participants must be between 18 and 75 years old and diagnosed with SEA, EGPA, or HES. Healthy donors within the same age range will be included as controls. Individuals with chronic lung diseases (such as COPD), other immune-mediated inflammatory conditions, recent infections, parasitic infestations, or immunosuppressive treatments will be excluded to ensure a clear focus on eosinophilic-driven inflammation.

Ethical Considerations and Study Management This study will adhere to ethical guidelines outlined in the Declaration of Helsinki and Good Clinical Practice (GCP) regulations. Informed consent will be obtained from all participants, ensuring they fully understand the study's purpose and procedures. Ethical approval will be secured from the relevant institutional review boards before the study commences.

Biological samples will not be stored beyond their immediate use, and strict chain-of-custody procedures will be followed. If a participant withdraws consent, their samples will be immediately destroyed unless they have already been analyzed.

Statistical Analysis and Expected Outcomes This is an exploratory pilot study, and an estimated 135 patients (80 SEA, 30 EGPA, 25 HES) and 25 healthy donors will be recruited. Statistical methods, including Mann-Whitney U tests, ANOVA, and Spearman correlation tests, will be used to analyze the data. The primary focus will be to determine the proportion of iEos and rEos in different disease states and evaluate their response to cytokine stimulation and Mepolizumab treatment.

If successful, this study could lead to a deeper understanding of eosinophil biology and its implications in eosinophilic disorders. More importantly, it could refine therapeutic strategies by identifying whether Mepolizumab specifically targets inflammatory eosinophils while preserving homeostatic ones, ultimately leading to more personalized treatment approaches for patients with EADs.

Study Type

Observational

Enrollment (Estimated)

160

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Each subject should meet all of the inclusion criteria and none of the exclusion criteria for this study. Under no circumstances can there be exceptions to this rule.

Description

Inclusion Criteria:

- For inclusion in the study subjects should fulfill the following criteria based on local regulations:

Patients with Asthma, or EGPA or HES:

  1. Age between 18 and 75 years at the time of signing the informed consent
  2. Patients with EA, EGPA or HES
  3. Provision of signed and dated written informed consent form prior to any mandatory study procedures, sampling and analysis.

Healthy donors:

1. Age between18 and 75 years healthy donors

Exclusion Criteria:

  • Subjects should not enter the study if any of the following exclusion criteria are fulfilled:

    1. Presence of other chronic pulmonary diseases including COPD
    2. Presence of other chronic immuno-mediated inflammatory diseases
    3. Treatment with oral prednisone or equivalent > 7.5 mg/day
    4. Treatment with long-acting depot corticosteroids in the last three months
    5. Use of immunosuppressive medications (cyclosporine A; azathioprine; methotrexate; mycophenolate mofetil)
    6. Receipt of live attenuated vaccines 30 days prior to the enrollment
    7. Acute upper or lower respiratory infections within 30 days prior to the date informed consent is obtained or during the screening/run-in period.
    8. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy
    9. Subjects who are pregnant or breastfeeding
    10. Current smoking
    11. Any clinically significant abnormal findings in physical examination, vital signs, hematology, or clinical chemistry during screening period, which in the opinion of the investigator may put the patient at risk of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study.
    12. Concurrent enrolment in another interventional or post-authorization safety study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Healthy donors
25 healthy subject
EA
80 eosinophilic asthma patients
EGPA
30 EGPA patients
HES
25 HES patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary objective: first outcome measure
Time Frame: From the enrollment of the first patient at 20 months
1) Proportion of circulating Siglec8+CD16-CD62Llow (iEos) and Siglec8+CD16-CD62Lbright (rEos) cells in bio- naïve, EGPA and HES patients
From the enrollment of the first patient at 20 months
Primary objective: second outcome measure
Time Frame: From the enrollment of the first patient at 20 months
2) Modification of the expression of CD62L on peripheral eosinophils upon in vitro stimulation with IL-5, IL-3, GM-CSF, IL-4, IL-13
From the enrollment of the first patient at 20 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary objective: first outcome measure
Time Frame: From the enrollment of the first patient at 18 months
1) Proportion of circulating Siglec8+CD16-CD62Llow (iEos) cells in bio-naïve EA, EGPA, and HES patients
From the enrollment of the first patient at 18 months
Secondary objective: second outcome measure
Time Frame: From the enrollment of the first patient at 18 months
2) Correlation between Siglec8+CD16-CD62Llow (iEos) cells and disease-specific clinical scores in bio-naïve EGPA, HES and EA patients
From the enrollment of the first patient at 18 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Explorative objective
Time Frame: From month 7 to month 20
1) Modification of the proportion of CD62Llow and CD62Lbright among eosinophils obtained from EGPA and HES patients, upon in vitro coculture with mepolizumab and type 2 cytokines.
From month 7 to month 20

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Florence

Collaborators

GlaxoSmithKline

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

March 21, 2025

First Submitted That Met QC Criteria

March 27, 2025

First Posted (Actual)

April 4, 2025

Study Record Updates

Last Update Posted (Actual)

April 4, 2025

Last Update Submitted That Met QC Criteria

March 27, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 26188-OSS

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypereosinophilic Syndrome (HES)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe